JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 125 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 6.50 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $101,000 | -19.2% | 14,942 | +0.2% | 0.00% | – |
Q4 2021 | $125,000 | +16.8% | 14,918 | +3.8% | 0.00% | – |
Q3 2021 | $107,000 | +35.4% | 14,372 | +24.1% | 0.00% | – |
Q2 2021 | $79,000 | -34.7% | 11,579 | -1.8% | 0.00% | – |
Q1 2021 | $121,000 | +40.7% | 11,787 | -3.9% | 0.00% | – |
Q4 2020 | $86,000 | -20.4% | 12,260 | -7.6% | 0.00% | – |
Q3 2020 | $108,000 | -51.8% | 13,274 | -59.1% | 0.00% | – |
Q2 2020 | $224,000 | +176.5% | 32,475 | +91.3% | 0.00% | – |
Q1 2020 | $81,000 | -50.0% | 16,978 | -8.7% | 0.00% | – |
Q4 2019 | $162,000 | +134.8% | 18,604 | -10.4% | 0.00% | – |
Q3 2019 | $69,000 | -25.8% | 20,762 | +10.2% | 0.00% | – |
Q2 2019 | $93,000 | -29.5% | 18,847 | -11.4% | 0.00% | – |
Q1 2019 | $132,000 | +230.0% | 21,264 | +80.6% | 0.00% | – |
Q4 2018 | $40,000 | -88.7% | 11,776 | -74.5% | 0.00% | – |
Q2 2018 | $354,000 | – | 46,230 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |